IC
CORT icon

Ikarian Capital’s Corcept Therapeutics CORT Stock Holding History

Ikarian Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-185,593
Closed -$6.46M – 177
2025
Q4 		$6.46M Buy
+185,593
New +$14.6M 0.5% 57

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Ikarian Capital's CORT Position: Q1 2026 in Review

Ikarian Capital sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 185,593 shares — an estimated $6.46M sold.

Ikarian Capital first reported a position in CORT in Q4 2025 and held it in 1 quarter. The position peaked at $6.46M in Q4 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Ikarian Capital reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 185,593 Corcept Therapeutics shares in Q1 2026, an estimated $6.46M.
  • Ikarian Capital first reported a position in Corcept Therapeutics in Q4 2025 and held it in 1 quarter.
  • Ikarian Capital's Corcept Therapeutics position peaked at $6.46M in Q4 2025.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.